Over recent years global drug companies large or small have recognized that one root cause of the high failure rate in their clinical development lies in the selection of right therapeutic targets.
Jim Zhang, Ph.D
Advertisement
Articles by Jim Zhang, Ph.D
Advertisement
Latest Updated Articles
Global Biomarker and Companion Diagnostics Outsourcing MarketPublished: January 22nd 2015 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Honing the Power of AI for Next Generation Trial Oversight and Execution
2
AstraZeneca’s Phase III POTOMAC Trial Shows Imfinzi Significantly Improves Disease-Free Survival in High-Risk NMIBC
3
ACT Brief: AI-Driven Oversight, Biotech Acceleration Strategies, and a Major Win in Bladder Cancer
4
Genentech’s Phase III MEERKAT and SANDCAT Trials Show Vision and Anatomical Gains With Vamikibart in Uveitic Macular Edema
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
